THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Genzyme’s in play, and it’s all about price

By Robert Weisman
Globe Staff / August 3, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

Executives at Genzyme Corp. and the French drug maker Sanofi-Aventis SA were locked in negotiations yesterday after Sanofi’s bid to buy the pioneering Cambridge company, which helped to turn the Massachusetts biotechnology industry into a global player. (Full article: 864 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly